-
2022-501531-16-00
5
2020-01-24
esophageal carcinoma
-
2024-514829-36-00
5
2019-12-02
High-risk biochemically-relapsed prostate adenocarcinoma following rad
-
2024-515616-47-00
5
2019-10-03
Metastatic Renal Cell Carcinoma
-
2024-512555-21-00
5
2019-09-18
Metastatic colorectal cancer
-
2024-514885-38-00
5
2019-07-11
severe forms of mucous membrane pemphigoid
-
2024-513728-40-00
5
2019-07-02
scheduled surgery for digestive cancer
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2024-510605-28-00
5
2018-11-27
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2024-516601-23-00
5
2017-11-14
Colorectal adenomas
-
2024-513964-24-00
5
2017-09-14
Squamous cell carcinoma, previously untreated
Stage III, stage IVa (op
-
2024-510645-34-00
4
2017-06-28
RAS and B-RAF wild-type metastatic colorectal cancer.
RAS and B-RAF mu
-
2024-517489-41-00
5
2017-03-27
High-risk stage III colon cancer
-
2024-518741-21-00
4
2014-12-23
colon cancer
-
2024-516198-61-00
5
2013-06-05
Patients with high risk of relapse, ER+ and HER2- primary non-metastat
-
2024-516996-34-00
5
2012-04-12
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
-
2024-514844-10-00
4
2010-03-18
Retinoblastoma
-
2024-514756-32-00
5
2007-03-19
High grade osteosarcoma
-
2023-508959-39-00
5
2025-02-20
Moderate to Severe Plaque Psoriasis
-
2023-506185-31-00
10
2024-07-18
Idiopathic pulmonary fibrosis (IPF)
-
2022-501196-41-00
5
2024-05-29
Dermatitis atopic
-
2023-505803-22-00
4
2024-04-15
Hidradenitis
-
2022-502370-17-00
4
2023-11-14
Hidradenitis suppurativa
-
2022-502372-22-01
4
2023-10-19
Metastatic Breast Cancer HR+, HER2-